Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular ...

An independent researcher said the results should spark a re-evaluation of some medicines, but do not necessarily mean ...

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and ...

Ocugen (OCGN) announced that the European Medicines Agency, EMA, has granted orphan medicinal product designation for OCU410ST for the ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, ...

Ocugen, Inc. (OCGN) announced the European Medicines Agency has granted orphan medicinal product designation for OCU410ST for the ...

Clinuvel Pharmaceuticals (ASX:CUV) has entered discussions with the European Medicines Agency to increase the recommended ...

Capricor Therapeutics (CAPT) stock in focus as company receives Orphan Drug and ATMP designations from the EU regulator for its lead drug deramiocel. Read more here.

Samsung Biologics has secured two deals valued at 930.4 billion won ($668.4 million) with an unnamed European pharmaceutical ...

BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization ...

UK MHRA grants marketing authorization to sparsentan to treat adult patients with primary immunoglobulin A nephropathy: United Kingdom Wednesday, November 20, 2024, 14:00 Hrs [IST ...

Samsung Biologics said on Wednesday it surpassed the 5 trillion won ($3.59 billion) mark in its accumulated orders this year ...